Results 211 to 220 of about 106,022 (294)

Association Between Glucagon-Like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obesity. [PDF]

Drug Des Devel Ther
Huang SC, Wu JY, Kuo CY, Hsu WH, Tsai YW, Lai CC.   +5 more
europepmc   +1 more source

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs). [PDF]

Drug Des Devel Ther
Li J, Fu K, Zhao J, Zou Y, Li L, Huang Q, Long L, Ou X, Lei M, Zhang C, Tan X, Chen T.   +11 more
europepmc   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source

Comparison of Perioperative Glycemic Control in Patients Continuing Versus Temporarily Holding Glucagon-Like Peptide-1 Receptor Agonists or Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists Preoperatively. [PDF]

AACE Endocrinol Diabetes
Trykall CC, Hill SB, James AM, Bagnola AJ, Wyne KL, Handley D, Brower KI.   +6 more
europepmc   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Bile Acid Diarrhea: Emerging Evidence and Clinical Implications. [PDF]

Cureus
Omeludike EK, Nwabueze CO, Ubah N, Okeke N, Aregbesola E, Onyiaorah CR, Igbokwe MA, Gujral M, Lawal RA, Akande YF.   +9 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. Materials and Methods This retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m2) initiated on tirzepatide against 50 age‐, sex‐ and BMI‐matched ...
Simon A. Berry, Iona R. Goodman, Eleanor McNally, Jackie Elliott, Ahmed Iqbal   +4 more
wiley   +1 more source

Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Cardiovasc Ther
Zawadzki M, Karczewska-Kupczewska M.
europepmc   +1 more source

The Upfront Effectiveness of a 6‐Week Continuous Glucose Monitoring Intervention for Non‐Insulin‐Using Individuals With Type 2 Diabetes Is No Longer Detectable at 6–12 Months: An Observational Follow‐Up of a Randomized Trial Cohort

Diabetes, Obesity and Metabolism, EarlyView.
Jiawei Ryan Zhang, Roseanne O. Yeung, Donna P. Manca, Pratima Singh, Inga Olu‐Jordan, Tawnya Perry, Gulelala Rahim, Evan M. Hagen, Darren Lau   +8 more
wiley   +1 more source